Parkinson's Disease Neuroprotection Clinical Trial

帕金森病神经保护临床试验

• 批准号: 7012766
• 负责人: MICHAEL Jeffrey AMINOFF
• 金额: $ 2.52万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7012766
• 关键词: Parkinson' s disease; antiinflammatory agents; chemoprevention; clinical research; clinical trials; cooperative study; human subject; human therapy evaluation; nervous system disorder therapy; neuropharmacology; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is the second most common neurodegenerative disorder. While a number symptomatic therapies have been developed, no treatment has been identified that halts or slows this progressive disorder. For a number of reasons, we believe that it is appropriate to begin a prospective clinical trial of one or more of the more promising agents to determine whether they offer benefit. The aim of this application is to participate as a clinical center in a collaborative study of neuroprotective agents. The agents and protocol will be specified by NINDS. UCSF has a long history in providing subspecialty care for subjects with PD. The UCSF Parkinson's Disease Clinic & Research Center (PDCRQ has been involved in a number of clinical trials to elucidate the neurologic dysfunction underlying PD as well as testing a variety of novel treatments for PD. This research has included a number of industry sponsored treatment trials for subjects with early to advanced PD. A large diverse, local population provides a reliable source of motivated subjects for clinical research. The experience of the UCSF PDCRC in evaluating, selecting and following subjects with PD make it an ideal candidate for a multicenter, prospective trial of a potential neuroprotectant therapy. The ideal neuroprotective treatment should be effective, inexpensive, well tolerated, safe, easy to administer, and have few interactions with common medications. A number of studies over the last decade 'in humans and experimental animals have demonstrated a local immunologic response mediated by microglia and a number of inflammatory cytokines. Moreover, several animal models of PD have demonstrated that anti-inflammatory medications can interfere with the local immunologic response, and that they may preserve function of dopaminergic neurons. Although emerging understanding of the pathogenesis of PD may provide an alternative candidate for a neuroprotectant therapy, we propose that an anti-inflammatory medication would be a rational and practical candidate for the Parkinson's disease Neuroprotection Trial.

描述（由申请人提供）：帕金森氏病（PD）是第二常见的神经退行性疾病。虽然已经开发出一种症状疗法，但尚未确定停止或减慢这种进行性疾病的治疗方法。由于多种原因，我们认为，开始对一个或多个更有前途的代理商进行预期的临床试验，以确定它们是否提供福利是适当的。该应用的目的是作为临床中心参与神经保护剂的合作研究。代理和协议将由NIND指定。 UCSF在为患有PD的受试者提供专科护理方面有很长的历史。 UCSF帕金森氏病诊所与研究中心（PDCRQ已参与了许多临床试验，以阐明PD的神经功能障碍，并测试PD的各种新型治疗方法。这项研究包括多种临床研究的临床研究，可提供多种多样的PD。 UCSF PDCRC在评估，选择和以下受试者的PD受试者中成为对潜在神经保护剂治疗的多中心前瞻性试验的理想候选者。 理想的神经保护疗法应有效，廉价，耐受性，安全，易于管理，并且与常见药物相互作用很少。在过去十年中，在人类和实验动物中进行了许多研究表明，小胶质细胞和许多炎性细胞因子介导的局部免疫反应。此外，几种PD动物模型表明，抗炎药可以干扰局部免疫反应，并且它们可以保留多巴胺能神经元的功能。尽管对PD发病机理的新认识可能为神经保护剂治疗提供了替代性候选者，但我们建议抗炎药将是帕金森氏病神经保护试验的合理且实用的候选者。